| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/24/2000 | WO2000009506A1 1h-imidazopyridine derivatives |
| 02/24/2000 | WO2000009504A1 Substituted 1,8-naphthyridin-4(1h)-ones as phosphodiesterase 4 inhibitors |
| 02/24/2000 | WO2000009503A1 Integrin receptor antagonists |
| 02/24/2000 | WO2000009501A1 N-substituted azabicycloheptane derivatives, production and use thereof |
| 02/24/2000 | WO2000009500A2 Nematicidal pyrazoles |
| 02/24/2000 | WO2000009499A1 N-substituted azabicycloheptane derivatives, production and use thereof |
| 02/24/2000 | WO2000009498A1 Prodrugs of proton pump inhibitors |
| 02/24/2000 | WO2000009497A1 Improved omeprazole process and compositions thereof |
| 02/24/2000 | WO2000009496A1 Substituted 4-amino-2-aryl-pyrimidines, their production and use and pharmaceutical preparations containing same |
| 02/24/2000 | WO2000009495A1 Isoquinoline derivatives with angiogenesis inhibiting activity |
| 02/24/2000 | WO2000009494A1 Method of manufacture of 1,3-oxathiolane nucleosides |
| 02/24/2000 | WO2000009493A1 Enantioselective synthesis |
| 02/24/2000 | WO2000009492A1 Tace inhibitors |
| 02/24/2000 | WO2000009491A1 Calcilytic compounds |
| 02/24/2000 | WO2000009489A1 New carboxylic acid derivatives carrying keto side-chains, their production and their use as endothelin-receptor antagonists |
| 02/24/2000 | WO2000009486A1 Substituted isoquinoline derivatives and their use as anticonvulsivants |
| 02/24/2000 | WO2000009485A1 Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors |
| 02/24/2000 | WO2000009484A1 Pipecolic acid derivatives and their use for vision and memory disorders |
| 02/24/2000 | WO2000009479A2 Heterocyclic thioesters or ketones for vision and memory disorders |
| 02/24/2000 | WO2000009475A1 Amine derivatives |
| 02/24/2000 | WO2000009167A1 Virally-mediated targeting of drugs and genetic material |
| 02/24/2000 | WO2000009163A1 Conjugated linoleic acid alkyl esters in feedstuffs and food |
| 02/24/2000 | WO2000009162A1 Preventives/remedies for glaucoma |
| 02/24/2000 | WO2000009161A1 Plasminogen activator inhibitor 1 production regulatory agents |
| 02/24/2000 | WO2000009153A1 Compositions and methods for treating lysosomal storage disease |
| 02/24/2000 | WO2000009145A1 Treatment of tumors with oligonucleotides directed to insulin-like growth factor-i receptor |
| 02/24/2000 | WO2000009139A2 Methods for promoting survival of myelin producing cells |
| 02/24/2000 | WO2000009137A2 Aminosterol compounds and uses thereof |
| 02/24/2000 | WO2000009136A1 Progestogen-only contraceptive kit providing good cycle control |
| 02/24/2000 | WO2000009135A1 Peridermal cell protecting agents |
| 02/24/2000 | WO2000009134A1 Use of misoprostol or/and misoprostol acid for preparing drug in order to cure sexual dysfunction in women |
| 02/24/2000 | WO2000009133A1 Sustained release oral preparations of fasudil hydrochloride |
| 02/24/2000 | WO2000009132A1 Calcilytic compounds |
| 02/24/2000 | WO2000009131A1 Diaminopyrimidines and combination therapies effective for treatment of p-glycoprotein positive cancers |
| 02/24/2000 | WO2000009130A2 New pharmaceutical uses for nos inhibitors |
| 02/24/2000 | WO2000009129A1 C3a receptor ligands |
| 02/24/2000 | WO2000009128A1 Treatment of fecal incontinence |
| 02/24/2000 | WO2000009127A1 Remedies for multiple sclerosis |
| 02/24/2000 | WO2000009126A1 N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders |
| 02/24/2000 | WO2000009125A1 Ureas and carbamates of n-heterocyclic carboxylic acids and isosteres for vision and memory disorders |
| 02/24/2000 | WO2000009124A1 Pyrrolidine derivatives for vision and memory disorders |
| 02/24/2000 | WO2000009123A1 Pharmaceutical compositions containing lipase inhibitors and chitosan |
| 02/24/2000 | WO2000009122A1 Pharmaceutical compositions containing lipase inhibitors |
| 02/24/2000 | WO2000009121A1 Anti-inflammatory analgesics |
| 02/24/2000 | WO2000009120A1 New use of taxoid derivatives |
| 02/24/2000 | WO2000009119A1 Hydroxamic acid derivatives as inhibitors of beta-amyloid production |
| 02/24/2000 | WO2000009118A1 Methods for reducing atherosclerotic plaques |
| 02/24/2000 | WO2000009117A1 Nimesulide containing topical pharmaceutical compositions |
| 02/24/2000 | WO2000009114A1 Methods for treating viral infections using a compound capable of inhibiting microtubules |
| 02/24/2000 | WO2000009113A1 Use of zeranol to modulate reproductive cycles |
| 02/24/2000 | WO2000009112A2 Heterocyclic esters or amides for vision and memory disorders |
| 02/24/2000 | WO2000009111A2 Inhibitors of amyloid formation |
| 02/24/2000 | WO2000009110A2 N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders |
| 02/24/2000 | WO2000009109A2 Pipecolic acid derivatives for vision and memory disorders |
| 02/24/2000 | WO2000009108A2 Compositions and uses for vision and memory disorders |
| 02/24/2000 | WO2000009107A2 Sulfonamides of n-containing heterocyclic thioesters for vision and memory disorders |
| 02/24/2000 | WO2000009106A2 Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders |
| 02/24/2000 | WO2000009105A2 Small molecule carbamates or ureas for vision and memory disorders |
| 02/24/2000 | WO2000009104A2 Use of sulfonamides for treating vision and memory disorders |
| 02/24/2000 | WO2000009103A2 N-linked sulfonamides of n-heterocyclic carboxylic acids or isosteres for vision and memory disorders |
| 02/24/2000 | WO2000009102A2 Carboxylic acids and isosteres of n-heterocyclic compounds for vision and memory disorders |
| 02/24/2000 | WO2000009101A2 Use of estrogenic compounds as anti-fungal agents |
| 02/24/2000 | WO2000009100A2 Benzothiepine compounds as enhancer of cell differentiation induction factor |
| 02/24/2000 | WO2000009099A2 Treatment of vasodilatory headache |
| 02/24/2000 | WO2000009098A2 Method for treating ocular neovascular diseases |
| 02/24/2000 | WO2000009097A2 Pharmaceutical composition with antitumor activity on the basis of carboplatin |
| 02/24/2000 | WO2000009096A1 Injectable formulations of nanoparticulate naproxen |
| 02/24/2000 | WO2000009093A1 Microemulsions as solid dosage forms for oral administration |
| 02/24/2000 | WO2000009092A1 Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles |
| 02/24/2000 | WO2000009091A1 Once daily analgesic tablet |
| 02/24/2000 | WO2000009089A1 Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient |
| 02/24/2000 | WO2000009087A1 Methods for forming regional tissue adherent barriers and drug delivery systems |
| 02/24/2000 | WO2000009086A2 Protected one-vial formulation for nucleic acid molecules, methods of making the same by in-line mixing, and related products and methods |
| 02/24/2000 | WO2000009085A2 Oral formulation containing cyclosporin |
| 02/24/2000 | WO2000009071A2 A novel liposomal formulation useful in treatment of cancer and other proliferation diseases |
| 02/24/2000 | WO2000009070A2 Inhibition of pathogenic processes related to tissue trauma |
| 02/24/2000 | WO2000008948A2 Carbohydrate mixture |
| 02/24/2000 | WO2000008928A1 Non-sedating diphenhydramine metabolites |
| 02/24/2000 | WO2000001392B1 1-octadecyl-2-methyl-sn-glycero-3-phosphocholine (et180ch3) for the treatment of human carcinoma of the breast |
| 02/24/2000 | WO2000000039B1 Process and product for promoting weight loss in overweight dogs |
| 02/24/2000 | WO1999065461A3 Cationic amphiphile micellar complexes |
| 02/24/2000 | WO1999064421B1 Acetylcholine enhancers |
| 02/24/2000 | WO1999064050A8 Novel potassium channel drugs and their uses |
| 02/24/2000 | WO1999062504A3 Topical administration of oxazolidinones for transdermal delivery |
| 02/24/2000 | WO1999062459A3 Agents and methods for protection, treatment and repair of connective tissue |
| 02/24/2000 | WO1999060988A9 Combination therapy for treatment of fiv infection |
| 02/24/2000 | WO1999059525A3 Broad spectrum microbicidal and spermicidal compositions, devices, and methods |
| 02/24/2000 | WO1999058684A3 Compounds from moraxella catarrhalis |
| 02/24/2000 | WO1999048868A3 Heterocyclic classes of compounds for the modulating tyrosine protein kinase |
| 02/24/2000 | WO1999045788A8 Food products having enhanced cocoa polyphenol content and processes for producing same |
| 02/24/2000 | DE19857750A1 Phosphatidylocholin als Arzneimittel mit schleimhautschützender Wirkung Phosphatidylocholin as a drug with mucosa protective effect |
| 02/24/2000 | DE19844116A1 Wirkstoffkombination insbesondere zur Prophylaxe und Therapie von ischämischen Organschäden und Reperfusionssyndromen Drug combination in particular for the prophylaxis and therapy of ischemic organ damage and reperfusion syndromes |
| 02/24/2000 | DE19837790A1 Manufacture of human pharmaceuticals, foodstuffs and cosmetics comprises the use of one or more physiologically compatible gases to enrich and potentiate the activity of the basic ingredients |
| 02/24/2000 | DE19837758A1 Verwendung von Wirkstoffkombinationen aus Flavonoiden und UV-Filtersubstanzen als antivirales Wirkprinzip Use of active compound combinations of flavonoids and UV filters as an antiviral action principle |
| 02/24/2000 | DE19837638A1 New arylsulfonamides and analogs, are cannabinoid receptor agonists used e.g. for treating neurodegenerative diseases, pain, convulsions or bacterial or viral infections |
| 02/24/2000 | DE19837627A1 New aminoacid esters of arylsulfonamides are useful for e.g. treating neurodegenerative diseases, pain, convulsions or bacterial or viral infections |
| 02/24/2000 | DE19837549A1 Use of quaternary nitrogen compounds for treatment and prevention of atopic eczema |
| 02/24/2000 | DE19837387A1 New nucleic acid analogs useful in therapeutic or diagnostic agents or electronic components, consist of 3'-deoxypentopyranosyl nucleosides |
| 02/24/2000 | DE19836339A1 Carbohydrate mixture comprising oligosaccharide and polysaccharide components with prebiotic properties useful as nutritional supplement or as pharmaceutical |
| 02/24/2000 | DE19834931A1 Verwendung von biogenen Estrogenen zur Hormonsubstitutionstherapie Use of biogenic estrogen for hormone replacement therapy |